연구동향 분석
박사

대장암 환자에서 Mass Spectrometry을 이용한 혈액순환 종양 DNA 분석 = Multi-gene analysis of circulating tumor DNA in colorectal cancer: Mass spectrometric based analysis

신수진 2015년

논문상세정보
인용/피인용
' 대장암 환자에서 Mass Spectrometry을 이용한 혈액순환 종양 DNA 분석 = Multi-gene analysis of circulating tumor DNA in colorectal cancer: Mass spectrometric based analysis' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • circulating tumor dna
  • colorectal neoplasm
  • kras mutation
  • massarray
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
32 0

0.0%

' 대장암 환자에서 Mass Spectrometry을 이용한 혈액순환 종양 DNA 분석 = Multi-gene analysis of circulating tumor DNA in colorectal cancer: Mass spectrometric based analysis' 의 참고문헌

  • Yen LC, Yeh YS, Chen CW, Wang HM, Tsai HL, Lu CY, Chang YT, Chu KS, Lin SR,Wang JY: Detection of KRAS oncogene in peripheral blood as a predictor of the response tocetuximab plus chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res2009, 15:4508-13.
  • Thierry AR, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F, Gillet B,Gongora C, Dechelotte P, Robert B, Del Rio M, Lamy PJ, Bibeau F, Nouaille M, Loriot V,Jarrousse AS, Molina F, Mathonnet M, Pezet D, Ychou M: Clinical validation of thedetection of KRAS and BRAF mutations from circulating tumor DNA. Nature medicine2014, 20:430-5.
  • Syrmis MW, Moser RJ, Whiley DM, Vaska V, Coombs GW, Nissen MD, Sloots TP,Nimmo GR: Comparison of a multiplexed MassARRAY system with real-time allelespecificPCR technology for genotyping of methicillin-resistant Staphylococcus aureus. ClinMicrobiol Infect 2011, 17:1804-10.
  • Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, Nik-Zainal S,Martin S, Varela I, Bignell GR, Yates LR, Papaemmanuil E, Beare D, Butler A, Cheverton A,Gamble J, Hinton J, Jia M, Jayakumar A, Jones D, Latimer C, Lau KW, McLaren S,McBride DJ, Menzies A, Mudie L, Raine K, Rad R, Chapman MS, Teague J, Easton D,Langerod A, Oslo Breast Cancer C, Lee MT, Shen CY, Tee BT, Huimin BW, Broeks A,Vargas AC, Turashvili G, Martens J, Fatima A, Miron P, Chin SF, Thomas G, Boyault S,Mariani O, Lakhani SR, van de Vijver M, van 't Veer L, Foekens J, Desmedt C, Sotiriou C,Tutt A, Caldas C, Reis-Filho JS, Aparicio SA, Salomon AV, Borresen-Dale AL, RichardsonAL, Campbell PJ, Futreal PA, Stratton MR: The landscape of cancer genes and mutationalprocesses in breast cancer. Nature 2012, 486:400-4.
  • Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B,Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, VanCutsem E, Bosman F: Prognostic role of KRAS and BRAF in stage II and III resected coloncancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00trial. J Clin Oncol 2010, 28:466-74.
  • Oeth P, del Mistro G, Marnellos G, Shi T, van den Boom D: Qualitative and quantitativegenotyping using single base primer extension coupled with matrix-assisted laserdesorption/ionization time-of-flight mass spectrometry (MassARRAY). Methods Mol Biol2009, 578:307-43.
  • Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, Liu CL, Neal JW,Wakelee HA, Merritt RE, Shrager JB, Loo BW, Jr., Alizadeh AA, Diehn M: An ultrasensitivemethod for quantitating circulating tumor DNA with broad patient coverage. Naturemedicine 2014, 20:548-54.
  • Macher H, Egea-Guerrero JJ, Revuelto-Rey J, Gordillo-Escobar E, Enamorado-Enamorado J, Boza A, Rodriguez A, Molinero P, Guerrero JM, Dominguez-Roldan JM,Murillo-Cabezas F, Rubio A: Role of early cell-free DNA levels decrease as a predictivemarker of fatal outcome after severe traumatic brain injury. Clin Chim Acta 2012, 414:12-7.
  • Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, SimesRJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ,Zalcberg JR: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. TheNew England journal of medicine 2008, 359:1757-65.
  • Jung KW, Won YJ, Kong HJ, Oh CM, Cho H, Lee DH, Lee KH: Cancer Statistics inKorea: Incidence, Mortality, Survival, and Prevalence in 2012. Cancer Res Treat 2015.
  • Holdhoff M, Schmidt K, Donehower R, Diaz LA, Jr.: Analysis of circulating tumorDNA to confirm somatic KRAS mutations. J Natl Cancer Inst 2009, 101:1284-5.
  • Heitzer E, Auer M, Gasch C, Pichler M, Ulz P, Hoffmann EM, Lax S, Waldispuehl-Geigl25J, Mauermann O, Lackner C, Hofler G, Eisner F, Sill H, Samonigg H, Pantel K, Riethdorf S,Bauernhofer T, Geigl JB, Speicher MR: Complex tumor genomes inferred from singlecirculating tumor cells by array-CGH and next-generation sequencing. Cancer Res 2013,73:2965-75.
  • Groot Koerkamp B, Rahbari NN, Buchler MW, Koch M, Weitz J: Circulating tumor cellsand prognosis of patients with resectable colorectal liver metastases or widespread metastaticcolorectal cancer: a meta-analysis. Ann Surg Oncol 2013, 20:2156-65.
  • Gabriel S, Ziaugra L, Tabbaa D: SNP genotyping using the Sequenom MassARRAYiPLEX platform. Curr Protoc Hum Genet 2009, Chapter 2:Unit 2 12.
  • Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M: Detection of high incidenceof K-ras oncogenes during human colon tumorigenesis. Nature 1987, 327:298-303.
  • Fabbri F, Carloni S, Zoli W, Ulivi P, Gallerani G, Fici P, Chiadini E, Passardi A,Frassineti GL, Ragazzini A, Amadori D: Detection and recovery of circulating colon cancercells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs. CancerLett 2013, 335:225-31.
  • Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N,Sokoll L, Szabo SA, Kinzler KW, Vogelstein B, Diaz LA, Jr.: Circulating mutant DNA toassess tumor dynamics. Nature medicine 2008, 14:985-90.
  • Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, Diaz LA, Jr., Goodman SN, DavidKA, Juhl H, Kinzler KW, Vogelstein B: Detection and quantification of mutations in theplasma of patients with colorectal tumors. Proceedings of the National Academy of Sciences26of the United States of America 2005, 102:16368-73.
  • Diaz LA, Jr., Bardelli A: Liquid biopsies: genotyping circulating tumor DNA. J ClinOncol 2014, 32:579-86.
  • Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D,Forshew T, Mahler-Araujo B, Rajan S, Humphray S, Becq J, Halsall D, Wallis M, Bentley D,Caldas C, Rosenfeld N: Analysis of circulating tumor DNA to monitor metastatic breastcancer. The New England journal of medicine 2013, 368:1199-209.
  • Chang CP, Chia RH, Wu TL, Tsao KC, Sun CF, Wu JT: Elevated cell-free serum DNAdetected in patients with myocardial infarction. Clin Chim Acta 2003, 327:95-101.
  • Bidard FC, Weigelt B, Reis-Filho JS: Going with the flow: from circulating tumor cellsto DNA. Science translational medicine 2013, 5:207ps14.
  • Beiter T, Fragasso A, Hudemann J, Niess AM, Simon P: Short-term treadmill running asa model for studying cell-free DNA kinetics in vivo. Clinical chemistry 2011, 57:633-6.
  • Baselga J, Rosen N: Determinants of RASistance to anti-epidermal growth factorreceptor agents. J Clin Oncol 2008, 26:1582-4.